-
1.
公开(公告)号:US20100260765A1
公开(公告)日:2010-10-14
申请号:US12669724
申请日:2008-07-23
CPC分类号: C07K16/2863 , A61K38/16 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
摘要翻译: 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地,本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号:US08119130B2
公开(公告)日:2012-02-21
申请号:US12669724
申请日:2008-07-23
IPC分类号: A61K39/395 , A61K39/00 , C12P21/08 , C07K16/00 , C07K16/28
CPC分类号: C07K16/2863 , A61K38/16 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
摘要翻译: 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地,本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。
-